Real-world experience with cefiderocol therapy for Pseudomonas aeruginosa and other multidrug resistant gram-negative infections within the Veterans Health Administration, 2019-2022.

ABSTRACT:

Objective

Single-center and regional studies have reported outcomes after treatment with cefiderocol, a novel siderophore cephalosporin. We report on real-world use, clinical outcomes, and microbiological outcomes with cefiderocol therapy within the Veterans' Health Administration (VHA).

Design

Prospective, observational descriptive study.

Setting

Veterans' Health Administration, 132 sites across the United States, during 2019-2022.

Patients

This study included patients admitted to any VHA medical center who received cefiderocol for ≥2 days.

Methods

Data were obtained from the VHA Corporate Data Warehouse and through manual chart review. We extracted clinical and microbiologic characteristics and outcomes.

Results

In total, 8,763,652 patients rece

SUBMITTER: Chou A 

PROVIDER: S-EPMC10173288 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature